IL309386A - Treatment of cognitive impairment with inhibitors of alpha-N-acetylgalactosaminid alpha-2,6-sialyltransferase 5 (ST6GALNAC5 - Google Patents
Treatment of cognitive impairment with inhibitors of alpha-N-acetylgalactosaminid alpha-2,6-sialyltransferase 5 (ST6GALNAC5Info
- Publication number
- IL309386A IL309386A IL309386A IL30938623A IL309386A IL 309386 A IL309386 A IL 309386A IL 309386 A IL309386 A IL 309386A IL 30938623 A IL30938623 A IL 30938623A IL 309386 A IL309386 A IL 309386A
- Authority
- IL
- Israel
- Prior art keywords
- alpha
- st6galnac5
- sialyltransferase
- inhibitors
- treatment
- Prior art date
Links
- 101710183129 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 Proteins 0.000 title 1
- 102100029229 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 Human genes 0.000 title 1
- 208000028698 Cognitive impairment Diseases 0.000 title 1
- 108010069296 ST6GalNAc V brain-specific GD1alpha synthase Proteins 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217937P | 2021-07-02 | 2021-07-02 | |
| PCT/US2022/035741 WO2023278713A1 (en) | 2021-07-02 | 2022-06-30 | Treatment of cognitive impairment with alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (st6galnac5) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309386A true IL309386A (en) | 2024-02-01 |
Family
ID=82742788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309386A IL309386A (en) | 2021-07-02 | 2022-06-30 | Treatment of cognitive impairment with inhibitors of alpha-N-acetylgalactosaminid alpha-2,6-sialyltransferase 5 (ST6GALNAC5 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230034093A1 (https=) |
| EP (1) | EP4363582A1 (https=) |
| JP (1) | JP2024524526A (https=) |
| KR (1) | KR20240042611A (https=) |
| CN (1) | CN117836411A (https=) |
| AU (1) | AU2022300980A1 (https=) |
| CA (1) | CA3223334A1 (https=) |
| IL (1) | IL309386A (https=) |
| WO (1) | WO2023278713A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100029748A1 (en) * | 2008-08-04 | 2010-02-04 | Sloan-Kettering Institute For Cancer Research | Metastasis Promoting Genes and Proteins |
-
2022
- 2022-06-30 WO PCT/US2022/035741 patent/WO2023278713A1/en not_active Ceased
- 2022-06-30 US US17/854,759 patent/US20230034093A1/en active Pending
- 2022-06-30 IL IL309386A patent/IL309386A/en unknown
- 2022-06-30 EP EP22748151.2A patent/EP4363582A1/en active Pending
- 2022-06-30 CN CN202280057214.5A patent/CN117836411A/zh active Pending
- 2022-06-30 AU AU2022300980A patent/AU2022300980A1/en active Pending
- 2022-06-30 JP JP2024500087A patent/JP2024524526A/ja active Pending
- 2022-06-30 KR KR1020247003955A patent/KR20240042611A/ko active Pending
- 2022-06-30 CA CA3223334A patent/CA3223334A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230034093A1 (en) | 2023-02-02 |
| KR20240042611A (ko) | 2024-04-02 |
| JP2024524526A (ja) | 2024-07-05 |
| AU2022300980A1 (en) | 2024-01-18 |
| EP4363582A1 (en) | 2024-05-08 |
| CA3223334A1 (en) | 2023-01-05 |
| CN117836411A (zh) | 2024-04-05 |
| WO2023278713A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202212876B (en) | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders | |
| EP4424328A3 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| IL315892A (en) | 5-MEO-DTM for the treatment of bipolar disorder | |
| IL316433A (en) | Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain | |
| WO2023122260A3 (en) | Inhibitors of sars-cov-2 | |
| IL309386A (en) | Treatment of cognitive impairment with inhibitors of alpha-N-acetylgalactosaminid alpha-2,6-sialyltransferase 5 (ST6GALNAC5 | |
| HK40110987A (en) | Treatment of cognitive impairment with alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (st6galnac5) inhibitors | |
| GB202205895D0 (en) | New medical uses | |
| GEAP202015119A (en) | Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition | |
| GB2616958B (en) | Fluid treatment | |
| EP4132497A4 (en) | ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER | |
| HK40097226A (en) | Use of luvadaxistat for the treatment of cognitive impairment | |
| GB202016159D0 (en) | Compound, compositions and methods for the treatment of pain | |
| MX2022015279A (es) | Diagnostico, prevencion y tratamiento de la infeccion por coronavirus. | |
| EP4578452A4 (en) | Corneal disorder treatment agent | |
| HK40086548A (en) | Use of agents for treatment of respiratory conditions | |
| PT4132495T (pt) | Endoxifeno para o tratamento de distúrbio bipolar i | |
| GB202417640D0 (en) | Fluid treatment | |
| HK40111171A (en) | Treatment of respiratory conditions | |
| GB202016164D0 (en) | Compound, compositions and methods for the treatment of depression | |
| IL317076A (en) | Aprociten for the treatment of hypertension | |
| GB202211102D0 (en) | Treatment, prevention and stabilization of various human diseases | |
| GB202110146D0 (en) | Treatment of respiratory conditions | |
| GB202304716D0 (en) | New treatment |